ACTUATE THERAPEUTICS, INC. ACTU

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen

synthase kinase-3 ("GSK-3"). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer

cells and block the function of the enzyme glycogen synthase kinase-3 beta ("GSK-3β"), a master regulator of complex

biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Last close 0.48 2026-10-23
Market cap $11.4M 2026-06-30 share count
52-week range 0.41 - 7.90

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.06

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
R&D $10.3M$18.7M$21.7M—
SG&A $12.2M$6.5M$3.3M—
Total operating expenses $22.5M$25.2M$25.0M—
Operating income -$22.5M-$25.2M-$25.0M—
Interest expense $20.2K$18.7K$43.6K—
Pre-tax income -$22.2M-$27.3M-$24.7M—
Income tax $800$800$0—
Net income -$22.2M-$27.3M-$24.7M—
EPS, basic -1.06-3.26-17.24—
EPS, diluted -1.06-3.26-17.24—
Shares, diluted (wtd. avg.) 21.0M8.4M1.4M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $13.2M$8.6M$3.0M$20.4M
Total current assets $13.6M$9.2M$3.0M—
Total assets $14.0M$9.3M$3.0M—
Accounts payable $1.5M$1.9M$3.4M—
Total current liabilities $5.7M$8.8M$6.9M—
Total liabilities $6.1M$9.2M$8.4M—
Retained earnings -$154.6M-$132.4M-$105.1M—
Total equity $7.9M$104.2K-$99.6M-$75.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$19.2M-$21.8M-$21.6M—
Stock-based compensation $6.0M$2.0M$423.5K—
Financing cash flow $23.7M$27.5M$4.1M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-002257.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 Net income, FY2023: -24.7M Net income, FY2024: -27.3M Net income, FY2025: -22.2M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — — —
Gross profit — — — —
Net income — -$24.7M -$27.3M -$22.2M

Recent filings and events

  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event Item 8.01
  • Material agreement signed Item 1.01
  • Other event Item 8.01
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%